Anagrelide
| Evidence Level: L5 | Predicted Indications: 50 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Anagrelide |
| DrugBank ID | DB00261 |
| Brand Names (EU) | Xagrid |
| Evidence Level | L5 |
| Predicted Indications | 50 |
| Top Prediction Score | 99.89% |
Approved Indication (EMA)
Xagrid is indicated for the reduction of elevated platelet counts in at-risk essential-thrombocythaemia (ET) patients who are intolerant to their current therapy or whose elevated platelet counts are not reduced to an acceptable level by their current therapy. An at-risk patient An at-risk ET is defined by one or more of the following features: >60 years of age or; a platelet count >1000 x 109/l or; a history of thrombohaemorrhagic events.
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | familial thrombocytosis | 99.89% | DL |
| 2 | reactive thrombocytosis | 99.83% | DL |
| 3 | inverse Klippel-Trenaunay syndrome | 99.59% | DL |
| 4 | thrombocythemia | 99.52% | DL |
| 5 | dermatofibrosarcoma protuberans | 98.91% | DL |
| 6 | rheumatoid arthritis | 98.86% | DL |
| 7 | rheumatoid factor-positive polyarticular juvenile idiopathic arthritis | 98.50% | DL |
| 8 | juvenile idiopathic arthritis | 98.48% | DL |
| 9 | osteoarthritis | 98.45% | DL |
| 10 | pseudoachondroplasia | 98.45% | DL |
| 11 | rheumatoid nodulosis | 98.14% | DL |
| 12 | juvenile chronic polyarthritis | 98.12% | DL |
| 13 | osteoarthritis susceptibility | 97.83% | DL |
| 14 | brachydactyly-syndactyly syndrome | 97.81% | DL |
| 15 | acromesomelic dysplasia, Hunter-Thompson type | 97.50% | DL |
| 16 | colobomatous microphthalmia-rhizomelic dysplasia syndrome | 97.50% | DL |
| 17 | juvenile arthritis due to defect in LACC1 | 97.35% | DL |
| 18 | myosclerosis | 97.25% | DL |
| 19 | brachyolmia-amelogenesis imperfecta syndrome | 97.14% | DL |
| 20 | brachyolmia | 97.05% | DL |
Showing top 20 of 50 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.